Back to search

Spain· ES:1251929001

ATTROGY 250 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

A diflunisal product containing diflunisal, registered in Spain by Purpose Pharma International Ab. The same ATC class is registered in 10 of our 19 countries.

ATC N02BA11

Checked against AEMPS CIMA (Spain) on

Informational only — not a medical device.

SOURCE REGISTER · ESAEMPS CIMA (Spain)normalisedATTROGY 250 MG COMPRIMIDOS RECUBIERTO…ATCN02BA11REGISTER NO.ES:1251929001PACKS LISTED0CHECKEDSeptember 12, 2026

Where it is registered

Diflunisal is registered in 10 of 19 countries.

Countries holding a registration under ATC N02BA11 (diflunisal), each read from that country’s own register.

  • This record: Spain, from AEMPS CIMA (Spain)
  • 7 of them publish a price we can compare per daily dose

Diflunisal · ATC N02BA11

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Spainprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

AEMPS CIMA (Spain)
Active substance
diflunisal
Manufacturer
Purpose Pharma International Ab
Country
Spain (ES)
ATC code
N02BA11
ATC class
Diflunisal
Defined daily dose
0.75 g, O
Reimbursed
Not published by this register
Source register
AEMPS CIMA (Spain)
Last checked
September 12, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

227 interactions on record for diflunisal.

Graded by severity as the source publishes them — 57 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Diflunisal · interactions on record

227 records

  • 57 severe
  • 144 moderate
  • 10 minor
  • 16 info

Most severe, free to view

  • DicoumarolB01AA01severe
  • WarfarinB01AA03severe
  • DalteparinB01AB04severe
  • EnoxaparinB01AB05severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/817bdef4-b33f-4c67-8e05-b5a4b6bf39a4
GET /v1/drugs/817bdef4-b33f-4c67-8e05-b5a4b6bf39a4?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cpresc": "Medicamento Sujeto A Prescripción Médica",
  "estado": "{\"aut\":1765364345000}",
  "nregistro": "1251929001",
  "substance": "diflunisal"
}

See everything about diflunisal.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.